Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SKYSCRAPER-02C
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- NCT04665856 ↗
- Completed
- Hoffmann-La Roche
- Focused
We haven't built an HCP commentary report on SKYSCRAPER-02C (tiragolumab plus atezolizumab in untreated extensive-stage small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SKYSCRAPER-02C so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Tiragolumab; Atezolizumab; Carboplatin; Etoposide; Tiragolumab Matching Placebo
- Arms
- Tiragolumab + Atezolizumab + Carboplatin and Etoposide · Experimental
- Placebo + Atezolizumab + Carboplatin and Etoposide · Placebo comparator
- Enrollment
- 123
- Primary outcomes
- Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)
- Overall Survival (OS) in the PAS
- Sponsor
- Hoffmann-La Roche
- Start
- Dec 21, 2020
- Primary completion
- Aug 31, 2023
- Results posted
- Yes
- Registry record
- NCT04665856 · updated Sep 18, 2026